Im sure that with normal drug development something like RWD would be a lot harder that's why trials are risky you go to do them find the answer (positive or negative) and then use it to inform next steps.
The SAS model and huge numbers taking up products is novel for cannabis drug discovery. The relationship with the clinical aspect surely will be driving this real-world data capture and early testing of what may/may not work and get good numbers while making potential $. Pretty novel in the drug discovery space and one that means you can rapidly spin up the waterwheel and then rapid learn and grow. while trials follow up at the end for cherry on the pie.
Cannabis market - $13B Pharma market - $360B
% of global wealth - tangible assets? like 5% % of global wealth - intangible - 95% (IP)
I know what pie I like.
IHL Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
